Search clinical trials for: JNJ39039039

Total 2 results

Janssen Scientific Affairs, LLC
Bayer

Completed

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department (MERCURY PE)

Pulmonary Embolism

United States
Janssen Scientific Affairs, LLC
Bayer

Completed

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (PIONEER AF-PCI)

Atrial Fibrillation | Percutaneous Coronary Intervention

United States, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Bulgaria, Malaysia, Romania, Russian Federation, South Africa, Turkey, Korea, Republic of, Australia, Canada, Netherlands, Denmark and more

3

Subscribe